Lonza Group LONN.SW
Lonza Group is a Swiss life sciences company offering contract development and manufacturing services (CDMO) for the pharmaceutical and biotechnology industries, as well as products and solutions for diagnostics and research. Lonza shows solid growth (earnings +39.2%, revenue +11.2%) and acceptable financial health (ND/EBITDA 1.54), but its demanding valuation (P/E 37.24) and negative free cash flow conversion (-65.56%) weigh on the overall profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Lonza Group is a Swiss life sciences company offering contract development and manufacturing services (CDMO) for the pharmaceutical and biotechnology industries, as well as products and solutions for diagnostics and research. Lonza shows solid growth (earnings +39.2%, revenue +11.2%) and acceptable financial health (ND/EBITDA 1.54), but its demanding valuation (P/E 37.24) and negative free cash flow conversion (-65.56%) weigh on the overall profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.3 |
| Quality / Moat | 4.6 |
| Valuation | 3.5 |
| Growth | 7.8 |
| Dividend | 5.2 |
| Momentum | 4.4 |
| Risk & Context | 6.5 |
OVERALL SCORE: 5.5/10
Context and risks
Moderate governance/regulatory risk in Switzerland. No material exposure to rates, oil, or geopolitics: Lonza's CDMO business does not depend on shipping routes or energy commodities.
News considered in the analysis
- PAHC or LZAGY: Which Is the Better Value Stock Right Now? — Listículo comparativo de Zacks sin información nueva sobre Lonza.
- Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings? — Opinión genérica sobre valoración, sin hechos concretos.
- 45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period — Observación sobre la divergencia precio-beneficio, sin información nueva.
- Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price — Estimación de valor intrínseco de un blog, sin catalizador concreto.
- Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum? — Análisis superficial de fundamentales, sin datos nuevos.
Verdict: Hold; wait for an improvement in cash generation or a valuation correction before entering.
Main risk: Negative free cash flow conversion (-65.56%) and a high P/E (37.24) expose Lonza to a correction if growth does not translate into cash flows.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →